[1]
De Berardis D, Fornaro M, Orsolini L, Valchera A, Carano A, Vellante F, et al. Alexithymia and suicide risk in psychiatric disorders: a mini-review. Front Psychiatry 2017; 8: 148.
[2]
De Berardis D, Olivieri L, Rapini G, Di Natale S, Serroni N, Fornaro M, et al. Alexithymia, suicide ideation and homocysteine levels in drug naïve patients with major depression: a study in the “real world” clinical practice. Clin Psychopharmacol Neurosci 2019; 17: 318-22.
[3]
De Berardis D, Martinotti G, Di Giannantonio M. Editorial: understanding the complex phenomenon of suicide: from research to clinical practice. Front Psychiatry 2018; 9: 61.
[4]
De Berardis D, Fornaro M, Valchera A, Cavuto M, Perna G, Di Nicola M, et al. Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. Int J Mol Sci 2018; 19: pii: E2888.
[5]
De Berardis D, Tomasetti C, Pompili M, Serafini G, Vellante F, Fornaro M, et al. An update on glutamatergic system in suicidal depression and on the role of esketamine. Curr Top Med Chem 2020.
[6]
De Berardis D, Serroni N, Campanella D, et al. Safety and efficacy of combined clozapine-azathioprine treatment in a case of resistant schizophrenia associated with Behcet’s disease: a 2-year follow-up. Gen Hosp Psychiatry 2013; 35: 213e9–213e11.
[7]
De Berardis D, Serroni N, Campanella D, et al. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 2012; 7: 55-62.
[8]
Marasco V, De Berardis D, Serroni N, et al. Alexithymia and suicide risk among patients with schizophrenia: preliminary findings of a cross-sectional study. Riv Psichiatr 2011; 46: 31-7.
